Create Free Account

By creating account you will get access to hot stocks & personalised emails

SIGA Technologies Inc

Healthcare US SIGA

5.87USD
-0.06(1.01%)

Last update at 2024-12-30T14:54:00Z

Day Range

5.755.90
LowHigh

52 Week Range

3.9310.83
LowHigh

Fundamentals

  • Previous Close 5.93
  • Market Cap538.40M
  • Volume45483
  • P/E Ratio6.88
  • Dividend Yield-%
  • EBITDA97.55M
  • Revenue TTM157.02M
  • Revenue Per Share TTM2.21
  • Gross Profit TTM 77.82M
  • Diluted EPS TTM1.10

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 44.13M 89.31M 73.51M -10.17842M 411.64M
Minority interest - - - - -
Net income 33.90M 69.45M 56.34M -7.24115M 421.81M
Selling general administrative 35.12M 17.32M 14.00M 13.25M 12.88M
Selling and marketing expenses - - - - -
Gross profit 77.82M 107.13M 99.22M 11.66M 368.77M
Reconciled depreciation 0.52M 0.52M 0.53M 0.53M 0.07M
Ebit 42.70M 89.09M 84.50M 0.50M 434.04M
Ebitda 43.73M 89.72M 85.56M 1.03M 434.11M
Depreciation and amortization 1.03M 0.62M 1.06M 0.53M 0.07M
Non operating income net other 1.43M 0.22M -7.97522M 2.82M 78.94M
Operating income 42.70M 89.09M 84.50M 0.50M 355.10M
Other operating expenses 68.08M 44.58M 40.46M 29.06M 121.95M
Interest expense -0.91831M 0.12M 3.02M 15.77M 15.48M
Tax provision 10.23M 19.86M 17.17M -2.93728M -10.16827M
Interest income - - - 10.68M 22.40M
Net interest income 0.00000M 0.00000M -3.01682M -15.76977M -15.47820M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 10.23M 19.86M 17.17M -2.93728M -10.16827M
Total revenue 110.78M 133.67M 124.96M 26.74M 477.05M
Total operating expenses 35.12M 18.03M 14.72M 13.98M 13.67M
Cost of revenue 32.96M 26.54M 25.74M 15.09M 108.29M
Total other income expense net 1.43M 0.22M -10.99204M -10.67851M 72.02M
Discontinued operations - - - - -
Net income from continuing ops 33.90M 69.45M 56.34M -7.24115M 421.81M
Net income applicable to common shares 33.90M 69.45M 56.34M -7.24115M 421.81M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 254.84M 195.04M 214.73M 149.83M 198.57M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.50M 2.32M 2.45M 2.11M 100.97M
Total liab 57.98M 24.88M 40.41M 20.04M 100.78M
Total stockholder equity 196.86M 170.16M 174.31M 129.79M 97.78M
Deferred long term liab - - - - -
Other current liab 31.31M 7.05M 24.23M 5.47M 5.92M
Common stock 0.00711M 0.00727M 0.00735M 0.00772M 0.00813M
Capital stock 0.00711M 0.00727M 0.00735M 0.00772M 0.00813M
Retained earnings -38.94362M -63.80499M -51.76326M -95.19288M -123.03241M
Other liab - 2.39M 7.79M 7.66M 9.05M
Good will 0.90M 0.90M 0.90M 0.90M 0.90M
Other assets - 6.50M 214.73M 3.22M 15.01M
Cash 150.15M 98.79M 103.14M 117.89M 65.25M
Cash and equivalents - - - - -
Total current liabilities 54.12M 21.52M 30.49M 10.48M 91.74M
Current deferred revenue 20.79M 10.58M 3.76M 3.28M 2.30M
Net debt -148.68184M -98.26245M -102.67199M -117.44030M 15.22M
Short term debt 0.56M 0.53M 0.47M 0.45M 80.46M
Short long term debt - - - - 80.04M
Short long term debt total 1.46M 0.53M 0.47M 0.45M 80.46M
Other stockholder equity 235.80M 233.96M 226.07M 224.98M 220.81M
Property plant equipment - 1.85M 2.37M 2.10M 2.62M
Total current assets 238.99M 185.79M 208.75M 143.61M 180.04M
Long term investments - - - - -
Net tangible assets - 170.16M 173.42M 128.89M 96.89M
Short term investments - - - - -
Net receivables 21.13M 45.41M 83.65M 3.34M 4.17M
Long term debt - - - - -
Inventory 64.22M 39.27M 19.51M 20.27M 9.65M
Accounts payable 1.46M 3.36M 2.03M 1.28M 3.05M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - -3.72631M
Additional paid in capital - - - - -
Common stock total equity - 0.00727M 0.00735M 0.00772M 0.00813M
Preferred stock total equity - - - - -
Retained earnings total equity - -63.80499M -51.76326M -95.19288M -123.03241M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.08M 0.25M 0.29M 0.68M 0.86M
Deferred long term asset charges - - - - 14.15M
Non current assets total 15.85M 9.25M 5.97M 6.22M 18.52M
Capital lease obligations 0.56M 0.53M 0.47M 0.45M 0.42M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00000M -0.05062M -0.01550M -0.02909M 78.24M
Change to liabilities -9.01485M 19.76M -1.22178M -0.92477M 5.52M
Total cashflows from investing activities - -0.05062M -0.01550M -0.02909M 78.24M
Net borrowings - - -85.91346M -85.91346M -85.91346M
Total cash from financing activities -45.95926M -26.19544M -114.60042M -1.17658M -3.81256M
Change to operating activities 0.17M 0.05M 0.70M -0.71427M -2.57933M
Net income 33.90M 69.45M 56.34M -7.24115M 421.81M
Change in cash -4.34820M -14.75142M -43.09669M -19.40998M 143.30M
Begin period cash flow 103.14M 117.89M 160.99M 180.40M 37.10M
End period cash flow 98.79M 103.14M 117.89M 160.99M 180.40M
Total cash from operating activities 41.61M 11.49M 71.52M -18.20430M 68.87M
Issuance of capital stock - - - - 0.00000M
Depreciation 0.52M 0.52M 0.53M 0.53M 0.07M
Other cashflows from investing activities - - - - 78.34M
Dividends paid -32.94040M 32.94M 32.94M 32.94M -
Change to inventory -19.96418M 0.14M -8.00999M -6.74464M 0.00004M
Change to account receivables 38.24M -80.31019M 0.83M -2.20886M -0.04972M
Sale purchase of stock -13.00633M -26.02152M -28.50295M - 0.26M
Other cashflows from financing activities -0.01253M -0.17392M -0.18402M -1.17658M -3.81256M
Change to netincome -2.04847M 1.39M 18.83M -0.30362M -7.02825M
Capital expenditures 0.00000M 0.05M 0.02M 0.03M 0.10M
Change receivables 38.24M -80.31019M 0.83M -2.20886M -0.04972M
Cash flows other operating -0.02738M 0.55M 4.22M -1.30826M -351.44911M
Exchange rate changes - - - - -
Cash and cash equivalents changes -4.34820M -14.75142M -43.09669M -19.40998M 143.30M
Change in working capital 9.44M -60.36675M -7.70493M -10.59254M 2.89M
Stock based compensation 1.78M 1.27M 1.35M 2.11M 2.27M
Other non cash items -0.19919M 0.50M 9.39M -0.59398M -348.86978M
Free cash flow 41.61M 11.44M 71.50M -18.23340M 68.77M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SIGA
SIGA Technologies Inc		 -0.06 1.01% 5.87 6.88 7.47 4.48 3.18 3.41 5.66
ZTS
Zoetis Inc		 -2.71 1.65% 161.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.35 1.20% 28.73 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 0.71 0.48% 147.25 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.105 0.79% 13.16 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

SIGA Technologies Inc

31 East 62nd Street, New York, NY, United States, 10065

Key Executives

Name Title Year Born
Dr. Phillip Louis Gomez III, M.D., Ph.D. CEO & Director 1967
Mr. Daniel J. Luckshire Exec. VP, CFO & Sec. 1971
Dr. Dennis E. Hruby Exec. VP & Chief Scientific Officer 1952
Ms. Tove C. Bolken Sr. VP of Operations & Chief Supply Chain Officer NA
Mr. Herb Vloedman Sr. VP & Chief Information Officer NA
Mr. Daniel J. Luckshire Executive VP, CFO & Secretary 1971
Dr. Dennis E. Hruby Executive VP & Chief Scientific Officer 1952
Dr. Jay K. Varma M.D. Executive VP, Chief Medical Officer & Director 1972
Dr. Diem Nguyen M.B.A., Ph.D. CEO & Director 1973
Ms. Tove C. Bolken Senior VP of Operations & Chief Supply Chain Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.